skip to content

New three-year data for Roche’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.